A Phase 1 interventional study of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes in Peripheral Neuropathy and Trigeminal Neuralgia, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Recruiting at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Peripheral Nervous System Diseases with a site in United States — 31 open to participants now, 48 under way, 2 of them phase 3. Peripheral Nervous System Diseases · United States.
Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, this one is the 117th largest by planned enrollment of the 157 interventional ones that give a count, is one of 11 that started in 2022, is one of 6 in phase 1, reaches primary completion later than 32 of the 46 other live ones, and was the 149th registered.
476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.
Browse Peripheral Nervous System Diseases studies →31 of the 191 studies in Peripheral Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18+
RxFunction Inc. · Sites in United States
Ages 60+
Yale University · Sites in United States
Ages 18+
Generate Biomedicines · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 40 · Phase 3 22 · Phase 4 4
First in 1984; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 57 across 359 interventional studies indexed under Peripheral Nervous System Diseases.
Median enrollment 43 across the 157 interventional studies, 80 across the 31 observational. Of the 129 that completed or were terminated, 58 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 191 have an industry lead sponsor. The 10 most frequent:
The Foundation for Orthopaedics and Regenerative Medicine is the lead sponsor of 33 studies on the registry; 19 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
The Foundation for Orthopaedics and Regenerative Medicine has 1 study filed under Peripheral Nervous System Diseases — fewer than ten, so there is no comparison to draw.
21 of the studies in Peripheral Nervous System Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06848348Dogwood Therapeutics Inc.Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | 2026-12 |
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
| NCT07674420Johns Hopkins UniversityWearable Insoles for Recurrent Diabetic Ulcer Prevention | 2027-01 |
| NCT04800484University of IowaThe Effects of AFO Heel Height and Stiffness on Gait | 2027-01-01 |
| NCT03584022Mayo ClinicClinical Trial to Assess the Safety of a Novel Scaffold Biomaterial | 2027-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will study the safety and efficacy of instillation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of Trigeminal Neuralgia.
This patient funded trial aims to study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell (MSCs) exosomes for the treatment of Trigeminal Neuralgia. Patients will receive an intranasal instillation of MSCs exosomes. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intranasal installation of exosomes
Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
Safety (adverse events)
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Started Sep 2022 (actual). Primary completion is estimated for Jan 2028, 64 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jan 2026 → Jan 2028 and completion Jan 2026 → Jan 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peripheral Nervous System Diseases →
The Foundation for Orthopaedics and Regenerative Medicine